CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing.

Autor: Liao CY; Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands., Engelberts P; Genmab, Utrecht, the Netherlands., Ioan-Facsinay A; Genmab, Utrecht, the Netherlands., Klip JE; Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands., Schmidt T; Leiden Institute of Physics, Leiden University, Leiden, the Netherlands., Ruijtenbeek R; Genmab, Utrecht, the Netherlands., Danen EHJ; Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. e.danen@lacdr.leidenuniv.nl.

Publikováno v: Communications biology [Commun Biol] 2024 Aug 13; Vol. 7 (1), pp. 983. Date of Electronic Publication: 2024 Aug 13.

Innovative strategies for measuring kinase activity to accelerate the next wave of novel kinase inhibitors.

Autor: Veth TS; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, Utrecht 3584 CH, The Netherlands; Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands., Kannegieter NM; Pepscope, Nieuwe Kanaal 7, 6709 PA Wageningen, The Netherlands., de Graaf EL; Pepscope, Nieuwe Kanaal 7, 6709 PA Wageningen, The Netherlands., Ruijtenbeek R; Genmab, Utrecht, The Netherlands., Joore J; Pepscope, Nieuwe Kanaal 7, 6709 PA Wageningen, The Netherlands., Ressa A; Pepscope, Nieuwe Kanaal 7, 6709 PA Wageningen, The Netherlands., Altelaar M; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, Utrecht 3584 CH, The Netherlands; Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands. Electronic address: m.altelaar@uu.nl.

Publikováno v: Drug discovery today [Drug Discov Today] 2024 Mar; Vol. 29 (3), pp. 103907. Date of Electronic Publication: 2024 Jan 30.

Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.

Autor: Hilhorst R; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands., van den Berg A; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands., Boender P; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands., van Wezel T; Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Kievits T; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands., de Wijn R; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands., Ruijtenbeek R; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands., Corver WE; Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Morreau H; Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2023 Sep 08; Vol. 15 (18). Date of Electronic Publication: 2023 Sep 08.

Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.

Autor: Diekstra MHM; Department of Pharmacology, Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., van der Zanden LFM; Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands., Vermeulen SH; Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands., Boven E; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands., Fukunaga K; Core for Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan., Mushiroda T; Core for Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan., Hongo F; Department of Urology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Oosterwijk E; Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands., Cambon-Thomsen A; CERPOP, Center of Epidemiology and Research in Population Health, Joint Unit 1295, Institut National de la Santé et de la Recherche Médicale (Inserm), Faculty of Medicine, Université de Toulouse, Université Toulouse III-Paul Sabatier, CEDEX, 31062 Toulouse, France., Castellano D; Medical Oncology Department, I+12 Research Institute, (CiberOnc), Hospital Universitario 12 de Octubre, 28041 Madrid, Spain., Fritsch A; Institute of Pharmacy, Clinical Pharmacy, University of Bonn, 53117 Bonn, Germany., Donas JG; Medical Oncology, HM Hospitales-Centro Integral Oncológico HM Clara Campal, 28050 Madrid, Spain., Rodriguez-Antona C; Hereditary Endorine Cancer Group, Spanish National Cancer Research Center (CNIO) and Biomedical Network on Rare Diseases (CIBERER), 28029 Madrid, Spain., Ruijtenbeek R; PamGene International B.V., 5211 HH 's-Hertogenbosch, The Netherlands., Radu MT; University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania., Eisen T; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0SL, UK., Junker K; Clinic of Urology and Paediatric Urology, Saarland University, 66424 Homburg, Germany., Roessler M; CESAR Central Office, CESAR Central European Society for Anticancer Drug Research-EWIV, 1010 Vienna, Austria., Jaehde U; Institute of Pharmacy, Clinical Pharmacy, University of Bonn, 53117 Bonn, Germany., Miki T; Department of Urology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan., Böhringer S; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Kubo M; Core for Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan., Kiemeney LALM; Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2022 Jun 08; Vol. 14 (12). Date of Electronic Publication: 2022 Jun 08.

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells

Autor: Steen, N., Potze, L., Giovannetti, E., Cavazzoni, A., Ruijtenbeek, R., Rolfo, C., Pauwels, P., Godefridus J Peters

Publikováno v: American Journal of Cancer Research, 7(4), 816-830. e-Century Publishing Corporation
Scopus-Elsevier
Van Der Steen, N, Potze, L, Giovannetti, E, Cavazzoni, A, Ruijtenbeek, R, Rolfo, C, Pauwels, P & Peters, G J 2017, ' Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells ', American Journal of Cancer Research, vol. 7, no. 4, pp. 816-830 .
Europe PubMed Central

Erlotinib is commonly used as a second line treatment in non-small cell lung cancer patients with sensitizing EGFR mutations. In EGFR-wild type patients, however the results are limited. Therefore we evaluated whether the combination of the Protein k

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::06eaecf44a3534168db87e10af3cea1c
https://research.vumc.nl/en/publications/10ebefe6-c607-4423-bedf-afcf439eaa84